drugset
drugset / Trial / NCT02352584

A Multicenter, Double-blind, Parallel Phase III Study

NCT02352584 ↗

Phase 3 Completed 1299 enrolled Green Cross Corporation
RandomizedParallel-groupTriple-blindPrevention

Summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III

Timeline

Start
2014-10
Primary completion
2014-12
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator GC3110A Vaccine 0.5 ml Intramuscular
Comparator GCflu Unknown 0.5 ml Intramuscular

Indications

influenza